Barrons : China Is in the AI Game. How Tech Giants Will Have to Play by Beijing’

China Is in the AI Game. How Tech Giants Will Have to Play by Beijing’s Rules.

What will artificial intelligence with Chinese characteristics look like? The past month or so has given us a better idea.

E-commerce giant Alibaba Group Holding (ticker: BABA) and facial-recognition pioneer SenseTime Group (0020.Hong Kong) joined search champion Baidu (BIDU) in releasing generative AI products, albeit in limited distribution. The Beijing government laid out draft regulations giving AI developers a green light, so long as their training data sets are “truthful, accurate, and objective”—quite a conundrum for the industry to bear in mind.

Investors aren’t looking for a Chinese equivalent to OpenAI, the proto-garage company that upended the U.S. tech establishment by unveiling ChatGPT half a year ago. In China, the establishment wins.

Retail investors have gone wild for domestically listed stocks with a whiff of AI, such as Cambricon Technologies (688256.China), whose shares have more than tripled this year.

The pros from abroad are staying away. “The current leading companies are the ones who can afford to be successful in AI,” says Sharukh Malik, a portfolio manager for Asian equities at Guinness Asset Management.

Markets were underwhelmed by Baidu’s Ernie bot. The company’s shares have slumped 6% since its March 6 release. Baidu nevertheless retains some first-mover advantage, says Charlie Chai, vice head of research at 86 Research in Shanghai. “Baidu has been investing in AI for the past decade, with hundreds of Ph.Ds,” he says.

Its in-house Kunlun semiconductors are also the best among China’s internet elite, which could be important as the U.S. squeezes chip exports to China.

The competition looks stiff, however. Tencent Holdings (700.Hong Kong), which dominates Chinese social media and online gaming, and TikTok parent ByteDance, are expected in the artificial intelligence ring soon, leveraging their enormous data troves and customer bases.

“All the first-tier players could end up as winners in their own focus area,” says Vivian Lin Thurston, an emerging markets portfolio manager at William Blair.

They’ll have to deal with the government first. Beijing’s AI push is a sort of ad hoc rehabilitation for China’s Big Tech, which was in the regulatory doghouse for the past two years. But the industry will have to leap forward Beijing’s way.

“The U.S. model is to learn from all the data sets, so the system can argue one way or another,” says Dylan Patel, chief analyst at SemiAnalysis.

That won’t be the Chinese model. The new regs make technology companies potentially liable if their bots produce answers that officials consider wrong, Chai says. “This will slow down releases as companies very carefully test their products,” he adds. No kidding.

Would-be Chinese AI champions need to keep an eye on Washington, too.

“The semis challenge is very real,” say AB Bernstein analysts, led by Robin Zhu. Advanced AI systems largely depend on microchips from a single U.S. designer, Nvidia (NVDA). Washington banned sales of that company’s A100 chip to China last year. Nvidia substituted the A800, which is one-third slower.

All these obstacles will slow, but not stop, Chinese companies’ march into AI. Patel estimates they are two years, at most, off OpenAI’s pace. “Baidu’s product is not as good as ChatGPT, but it’s pretty good,” he says.

Two years is too long, in tech time, to place bets on any horse race between the Chinese giants, Guinness’ Malik says. “I would give it a year to see who’s the most competent,” he says.

But the training laps will be worth watching. b

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • BLBD +32.8%, OUST +10.4%, AMLX +9.3%, ERJ +5.2%, SANM +3.3%, NWSA +3.3%, HRTX +3.1%, FSLR +2%, GSK +1.7%, BE +1.7%, LLAP +1.6%, ARLO +1.4%, SLF +1.1%, VTYX +1.1%, PBA +0.9%, YPF +0.8%
  • Gapping down:
    • HROW -9.5%, ANAB -8.6%, IONQ -8.4%, AU -6.8%, ANIP -6.4%, WEST -3.4%, DTC -3.3%, MIR -3%, RCEL -2.4%, NMM -1.7%, SOUN -1.6%, IAG -1.6%, WERN -1.5%, VCYT -0.9%, MDRX -0.8%

FT : Notes from the CEO on another failed THG takeover approach

Notes from the CEO on another failed THG takeover approach
“No shit! Ingenuity is great”

If you stopped at THG’s announcement that it had terminated talks to sell itself to Apollo, you're missing half the fun.

Matt Moulding, the increasingly embittered founder and CEO of the mascara-to-ping-meals conglomerate, has committed a very long LinkedIn post that explains the reasons why staying listed in London, in spite of its myriad failings, is still preferable to going private. Here are just a few highlights:

Just about every major PE firm has enquired about taking THG private. Usually, nobody finds out. But if there’s a leak, then the Takeover Panel forces an announcement. This is what happened with Apollo.

PE interest isn’t surprising. For the 3 years before IPO, THG shares traded at £3. Having doubled in size we then listed THG at £5 a share in Sep 20. They rose to £8 in the first-year post IPO but, after the Numis led short attacks when they weren’t made a Broker to THG, shares fell to as low as 30p in late 2022.

We're checking with Numis whether it agrees with the characterisation here of “Numis led short attacks when they weren't made a broker to THG”.

The last time THG shares traded at 30p was in 2009, when the Group had £80m Sales and only sold CDs! Today THG is 28 x bigger (and we haven’t sold CDs for years).

THG was a private company in 2009 so presumably he means the post-money valuation on a fundraising. A reminder that THG cancelled flotation plans two years later after discovering that its valuation had been inflated by fraud.

Like with all previous bidders, the Apollo bid wasn’t right for THG. Yes, it allowed existing shareholders to stay invested, with me continuing to run the Group. But Apollo also wanted PE controls, particularly across Beauty & Nutrition where they asked for controlling equity rights.

Like all previous bidders, Apollo were told their bid valuation and structure was unacceptable. Yesterday Apollo set out how they could raise their bid further, ahead of a deadline set by the Takeover Panel. Their latest view on Ingenuity had it as being significantly more valuable than the whole of THG the day before the bid leaked!

No shit! Ingenuity is great. But neither Apollo’s bid price, nor the structure proposed, are in the best interest of THG. Myself, Charles and the Board, supported by>50% of shareholders, all agreed on that.

The LinkedIn post comes with a photo of an injured Moulding that raises the possibility he has literally shot himself in the foot. Metaphorically, time will tell.

>>> Europe : Brokers Upgrades & Downgrades - 12th of May 2023 V2(+)

>>> Up
* Acerinox Raised to Overweight at Morgan Stanley; PT 12.80 euros
* American States Water Raised to Equal-Weight at Wells Fargo
* Barclays Raised to Outperform at RBC; PT 230 pence
* Crest Nicholson Raised to Buy at Berenberg; PT 310 pence
* Euronav Raised to Buy at Deutsche Bank; PT $20
* Fortum Raised to Buy at Inderes; PT 16 euros (+)
* Golden Ocean Raised to Hold at Pareto Securities (+)
* Molson Coors PT Raised to $74 from $68 at Jefferies
* Outokumpu Raised to Overweight at Morgan Stanley; PT 7.80 euros
* Pearson Raised to Overweight at Morgan Stanley; PT 920 pence
* Redrow Raised to Buy at Berenberg; PT 643 pence
* SpareBank 1 Nord Norge Raised to Buy at ABG; PT 106 kroner
* TGS Raised to Buy at Pareto Securities; PT 200 kroner (+)
* WDP Raised to Sector Perform at RBC; PT 27 euros

>>> Down
* Aperam Cut to Equal-Weight at Morgan Stanley; PT 42 euros
* Coloplast Cut to Hold at ABG; PT 900 kroner
* Coloplast Cut to Underweight at JPMorgan; PT 775 kroner (+)
* Derwent London Cut to Neutral at Goldman; PT 2,380 pence
* Diageo ADRs Cut to Hold at Jefferies; PT $190
* Diageo Cut to Hold at Jefferies; PT 3,800 pence
* DIC Asset Cut to Hold at Bankhaus Metzler; PT 7.60 euros (+)
* Great Portland Cut to Neutral at Goldman; PT 520 pence
* Salmar Cut to Hold at Nordea
* SOITEC Cut to Underweight at JPMorgan; PT 100 euros

>>> Initiation
* Dowlais Rated New Buy at Stifel; PT 175 pence (+)
* Geberit Rated New Sell at Citi; PT 420 Swiss francs
* MSCI Rated New Hold at Baptista Research; PT $510
* Puma Rated New Buy at Bankhaus Metzler; PT 68 euros (+)

>>> Call
* Barclays Upgraded at RBC on Unsung Structural Hedge Benefits
* Berenberg More Positive on UK Homebuilders; Redrow, Crest Raised
* Citi Sees A Race to Raise Cash as Debt Ceiling Nears: ECM Watch
* DB Strategists See Bigger Drop in Europe Earnings in Second Half (+)
* Diageo Cut to Hold at Jefferies as US Growth Rate Normalizes
* Geberit Initiated With Sell Rating by Citi on Multiple Headwinds
* Metro Sales Better Than Expected, Earnings a Beat, Baader Says
* Outokumpu, Acerinox Raised at Morgan Stanley, Aperam Downgraded
* Pearson Raised at Morgan Stanley on Overlooked AI Opportunities

>>> Stoxx 600 Pre-Market Indications

  • Rolls-Royce (RRU TH) +2.7%
    • Rolls-Royce Recovery Driven by Long-Haul Travel: Company Outlook
  • BAT (BMT TH) +1.4%
    • Reynolds Files Lawsuit in California to Protect Its Lawful Non-Menthol Products
  • Pearson (PES TH) +1.2%
    • Pearson Raised at Morgan Stanley on Overlooked AI Opportunities
  • Rio Tinto (RIO1 TH) +1%
    • Watch European Copper Stocks Ahead of LME Asia Week in Hong Kong
  • Erste (EBO TH) +0.9%
  • Puma (PUM TH) +0.9%
    • Puma Rated New Buy at Bankhaus Metzler; PT 68 euros
  • Aurubis (NDA TH) +0.8%
    • Watch European Copper Stocks Ahead of LME Asia Week in Hong Kong
  • Wacker Chemie (WCH TH) +0.8%
  • Orsted (D2G TH) -0.6%
  • Danone (BSN TH) -0.7%
  • SocGen (SGE TH) -1.1%
    • SocGen Debt Traders Beat Peers as First-Quarter Profit Gains (1)
  • Coloplast (CBHD TH) -1.4%
    • Coloplast Cut to Underweight at JPMorgan; PT 775 kroner
    • Coloplast Cut to Hold at ABG; PT 900 kroner
  • Salmar (JEP TH) -1.5%
    • Salmar Cut to Hold at Nordea